Clinical Trial: A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti(R)) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559799) titled 'A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti(R)) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)' on April 20.

Brief Summary: Multiple myeloma is the second most common hematologic malignancy in adults and despite the new therapies that have been developed in the last decades it remains incurable. Over the course of the disease, patients eventually become refractory to the various treatments. Therefore, new therapeutic options which utilize new mechanisms of action are essential.

Melphalan flufenamide (melflufen) represents such an additional therapeutic approach. Mel...